This is a summary of the European public assessment report (EPAR) for Lonquex. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Lonquex.
For practical information about using Lonquex, patients should read the package leaflet or contact their doctor or pharmacist.
Lonquex : EPAR - Summary for the public (PDF/99.29 KB)
First published: 02/09/2013
Last updated: 02/09/2013
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Sicor Biotech UAB
|Date of issue of marketing authorisation valid throughout the European Union||
22/02/2018 Lonquex - EMEA/H/C/002556 - P46/09
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Colony stimulating factors
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).